Making the business case for pharmaceutical supply planning

Executive perspective

For experienced pharmaceutical planners, the case for a new planning system rarely rests on whether the team knows how to plan. It rests on whether the current tools can deliver the speed, precision, control, and visibility the business now needs. Spreadsheets remain valuable for analysis, specialized calculations, and rapid problem solving. The investment question is different. When planning spans more products, sites, suppliers, CDMOs, constraints, and users, does the organization have a shared platform that can apply planning logic consistently, test alternatives quickly, preserve assumptions, and give management a current view of risk?

A purpose-built planning system should improve the decisions that already matter to the business, including how much to buy and when, which production campaigns to schedule, how to respond to changing demand, where supplier quotas or CDMO capacity make a plan infeasible, how much inventory is still usable before expiry, and whether an accelerated launch can be supported. The business case should therefore be built around operating and financial outcomes, not software features.

01Make scenario planning faster and more repeatable

Experienced planners already perform what-if analysis. The opportunity is to reduce the effort required to create, recalculate, compare, and explain scenarios. A purpose-built platform can duplicate an approved plan, change defined assumptions, recalculate time-phased requirements, and compare the result with the baseline without disturbing the operating plan. Inputs and outputs are retained, making the analysis easier to repeat and defend. High-value scenarios include:

• Demand upside or downside by product, market, or presentation.
• Accelerated approval or launch, with long-lead purchases and CDMO capacity pulled forward.
• Supplier delays, quota reductions, minimum-order changes, or constrained allocation.
• Lower yield, batch failure, quality hold, or delayed release.
• Loss of a CDMO campaign slot or changes in manufacturing sequence.
• Shelf-life exposure created by delayed demand or early production.

The value is decision speed. Instead of rebuilding calculations, planners can evaluate actions such as reserving capacity, pulling in a purchase, changing campaign timing, reallocating inventory, negotiating supply, or escalating an infeasible assumption.

Launch readiness can make that speed commercially important. In a 2014 study, McKinsey analyzed 492 drug launches across 131 therapeutic classes and found that first entrants held an average six-percentage-point market-share advantage ten years after launch, although late entrants still led more than half of the classes studied. The advantage was sizable when the lead was three years or more, while a gap of one year or less made little difference¹.

The goal is to make sure planning never becomes the reason the company misses a feasible market window. FDA data also show how frequently timelines can compress: 66% of novel drugs approved in 2024² and 72% in 2025³ used at least one expedited program. Scenario planning can show what an accelerated date would require in APIs, components, CDMO capacity, packaging, testing, release, and inventory.

02Put critical planning data under control

Demand signalsCommercial and clinical forecasts, enrollment patterns

Supply constraintsLead times, CDMO capacity, supplier quotas

Quality and shelf lifeBatch shelf life, GMP principles, yield variability

Master dataMaterials, BOMs, and planning parameters

SCmple MRP engineRequirements calculated across every BOM level

The actionable supply plan

• Automated FEFO logic
• Yield-adjusted production
• Scenario simulations

In most organizations the data exists. The harder question is whether the parameters that drive the plan are governed, current, and applied consistently. A purpose-built planning platform can manage:

• Materials, products, approved suppliers, and sourcing relationships.
• Multi-level bills of material and effective dates.
• Purchasing, manufacturing, testing, release, and transportation lead times.
• Minimum order quantities, order multiples, campaign sizes, and batch quantities.
• Expected yields and yield variability.
• Shelf life, expiry, batch status, and quality availability.
• Supplier quotas, allocation limits, and CDMO capacity calendars.

This gives planners a controlled model of the assumptions behind the plan and makes unexpected results easier to trace. A shortage or planned order can be tied back to the relevant demand signal, BOM, batch, lead-time offset, supplier rule, or capacity constraint.

The planning platform does not need to replace ERP as the transactional system of record. It can integrate inventory, purchase orders, production orders, and master data from ERP while maintaining planning-specific attributes at the level of detail required for supply planning. For companies that do not have an ERP for manufacturing, the SCmple platform can be used to create and maintain master data.

03Improve plan feasibility and reduce working-capital exposure

Planning precision means representing operating constraints accurately enough to expose risk early, even when the forecast is uncertain. Expiry-aware planning is a good example. Aggregate inventory is not sufficient if specific batches will not remain usable through production, release, shipment, or demand. The plan should recognize usable inventory by batch and expiry rather than treating all on-hand inventory as equivalent. That creates a stronger basis for reducing buffers without increasing service risk.

The same principle applies to lead times. Separating each lead-time component can produce more precise planned-order timing than broad, conservative offsets. Supply-demand pegging then explains why those orders exist and the exposure created when a purchase or campaign changes.

CDMO capacity, campaign constraints, and supplier quotas are equally important. A mathematically balanced plan is not feasible if no qualified manufacturing slot exists or if the recommended order exceeds supplier allocation. Constraint-aware planning identifies those conflicts in the same model used to generate requirements, giving planners time to negotiate, reserve, reallocate, or explicitly accept the risk.

04Give the planning process a scalable operating model

As teams and networks expand, cloud planning changes how the process operates. Multiple planners, sites, and authorized stakeholders can work from a common environment rather than reconciling copies of the plan. A multi-location model can represent inventory, supply, production, and demand by plant, warehouse, CDMO, or market while preserving an enterprise view. This also improves continuity as planning logic, assumptions, and scenarios remain in the shared platform rather than residing primarily on one person’s desktop. New planners or managers can work within an established structure instead of reconstructing the process from local files.

Leadership benefits from the same data foundation. Analytic dashboards can surface projected shortages, expiry exposure, capacity utilization, supplier constraints, inventory trends, and scenario comparisons. Management reviews can focus on decisions rather than reconciliation.

SCmple is also developing AI capabilities that help planners explore results and identify likely exception drivers. They are designed to support planner judgment, with faster diagnosis, easier navigation through the planning model, and more efficient transfer of knowledge.

05Capture more planning experience in the system

One less-visible benefit of a mature SaaS planning platform is the experience embedded in the product itself. A spreadsheet can be highly effective, but its planning logic usually reflects the methods and experience of its owner or immediate team. A SaaS platform is designed by industry specialists and then refined through implementations and feedback from many planners working across different products, networks, and operating conditions.

That accumulated experience is reflected in the data model, calculations, workflows, controls, and product updates. The system gives the planner a tested framework and helps the organization keep its planning knowledge instead of rebuilding it each time someone leaves.

06Build the investment case around measurable outcomes

A credible proposal should connect planning capabilities to baseline operating measures and business owners. Potential measures include:

Not every benefit will be a hard-dollar return. The case becomes stronger when each value claim has a baseline, a management owner, and a way to measure improvement after implementation.

A supply chain leader at a commercial-stage biopharmaceutical company described how his team made the case. They began with a detailed requirements document, split into must-haves and nice-to-haves, and measured every option against it. Leadership was involved from the start, so the discussion covered why the current approach would not scale with new markets and SKUs, what a stock-out would mean for patients and for a company that depends on one product, and what would happen if the planners who carried the plan left the business. By the time the final proposal reached leadership, they had already followed the reasoning, and approval came quickly.

Total cost should include subscription, implementation, data preparation, integration, internal resources, training, and administration. Time to value matters as much as license price. A right-sized platform can create a stronger return than a broader enterprise suite when it addresses the planning requirements that actually drive decisions with less implementation burden.

07Why SCmple

SCmple was purpose-built for clinical and commercial pharmaceutical supply planning by professionals with direct industry experience. It supports batch-based, shelf-life-constrained, externally manufactured supply chains without the cost and cross-industry complexity of large enterprise planning platforms.

Delivered as a SaaS cloud solution, SCmple combines planning, master data management, analytics, and quality and shelf-life rules on a common foundation. Capabilities include MRP, supply-demand pegging, yield-adjusted planning, expiry logic, scenario planning, supplier quotas, CDMO capacity, multi-location planning, and dashboards, with AI capabilities in development and AI-driven demand planning through Analytical Factor to follow.

For growing pharmaceutical manufacturers, four advantages stand out.

• Purpose-built for pharma. Planning logic reflects batch, shelf-life, yield, supplier, CDMO, and GMP realities.
• Integrated. Planning, master data, and analytics share one data foundation.
• Fast deployment. Implementation is typically measured in weeks rather than many months or years.
• Right-sized economics. Annual recurring cost is substantially lower than large cross-industry planning platforms.

The objective is to give experienced planners a stronger operating platform for applying their expertise, with faster scenarios, better-controlled planning data, earlier visibility of constraints, more precise inventory and production decisions, and clearer management insight.

Conclusion

The decision to upgrade planning should be justified by better decisions, not by technology alone. If a purpose-built platform can materially improve scenario speed, data control, plan feasibility, inventory and expiry management, collaboration, and leadership visibility, the business case becomes tangible. For growing pharmaceutical manufacturers, SCmple provides a right-sized path to those capabilities without requiring a large enterprise transformation.

References

1. McKinsey & Company. Pharma’s first-to-market advantage. September 2014. mckinsey.com
2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Advancing Health Through Innovation: New Drug Therapy Approvals 2024. January 2025. fda.gov
3. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Advancing Health Through Innovation: New Drug Therapy Approvals 2025. January 2026. fda.gov